|Systematic (IUPAC) name|
|Pregnancy cat.||C (US)|
|Legal status||℞ Prescription only|
|Mol. mass||723.644 g/mol|
| (what is this?)
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. Valstar was relaunched on September 3, 2009.
800 mg weekly for 6 weeks
Side effects 
- "Manufacturing Issues Remain for Indevus' Valstar", U.S. Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008
- "Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors" (Press release). 2009-09-03. Retrieved 2009-11-26.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|